布鲁顿酪氨酸激酶抑制剂单药治疗初诊华氏巨球蛋白血症患者的疗效和安全性

OBJECTIVE: To investigate the efficacy and safety of Bruton tyrosine kinase inhibitors (BTKi) ibrutinib or zanubrutinib monotherapy in newly diagnosed patients with Waldenström macroglobulinemia (WM). METHODS: The efficacy and adverse effects of 58 patients with newly diagnosed WM receiving BTKi mon...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2023
Materias:
论著
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450554/
https://www.ncbi.nlm.nih.gov/pubmed/37550205
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.06.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450554/
https://www.ncbi.nlm.nih.gov/pubmed/37550205
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.06.008

Ejemplares similares